AngioDynamics (ANGO) Reports In-Line Q1 EPS, Offers Q2 and FY16 Guidance
FREE Breaking News Alerts from StreetInsider.com!
StreetInsider.com Top Tickers, 6/23/2026
- Wall Street ends lower on semiconductor selloff as AI spending concerns mount
- Alphabet added to Dow Jones Industrial Average, Verizon dropped
- Chip stocks plunge, but bargain-hunters limit scale of tech rout
- FedEx falls 4% as CY2026 profit forecast misses expectations despite Q4 beat
- Oil prices finish 1% lower as investors focus on Hormuz flows after peace talks
- Exclusive-China robot-hand-building unicorn Linkerbot targets $6 billion valuation
- Spain's ex-transport minister sentenced to 24 years for corruption
- China, US, UAE police arrest 276 telecom fraud suspects in Dubai
- Needham Starts NeoVolta (NEOV) at Buy
- Li Auto Inc. (LI) Breaks Ground on Chips R&D and Production Base
Canaccord Genuity Cuts Price Target on AngioDynamics (ANGO) Following 1Q16
October 9, 2015 8:55 AM EDTCanaccord Genuity maintained a Buy rating on AngioDynamics (NASDAQ: ANGO), and cut the price target to $17.50 (from $19.00), following the company's 1Q16 earnings results. ANGOs salesforce has now converted approximately 45% of Morpheus customers over to BioFlow, with BioFlow PICC sales up 22% during the quarter.... More
Piper Jaffray Cuts Price target on AngioDynamics (ANGO) Following 1Q16 Results
October 9, 2015 8:12 AM EDTPiper Jaffray maintained a Neutral rating on AngioDynamics (NASDAQ: ANGO), and cut the price target to $14.00 (from $18.00), following the company's 1Q16 earnings results. Revenues missed, coming in at $83.7M, and earnings were in line with expectations.
Analyst Thomas Gunderson commented, "ANGO essentially... More
